nogalamycin and Kidney-Neoplasms

Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m2 by one-hour, intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was two months, and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis at the infusion site was seen in 47% of patients. Menogaril as administered in this protocol is ineffective in advanced renal cell carcinoma.

Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Evaluation; Female; Humans; Kidney Neoplasms; Leukocyte Count; Male; Menogaril; Middle Aged; Nogalamycin; Platelet Count

The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was observed. Mild or moderate degrees of thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule has no role in the treatment of patients with advanced metastatic renal cancer.

Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Daunorubicin; Drug Evaluation; Humans; Kidney Neoplasms; Menogaril; Nogalamycin